Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota

Immunological Reviews

Volumn 206, Issue , 2005, Pages 260-276

  Elson, Charles O ^a   Cong, Yingzi ^a   McCracken, Vance J ^b   Dimmitt, Reed A ^c   Lorenz, Robin G ^b   Weaver, Casey T ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CD4 ANTIGEN; CD45 ANTIGEN; CYTOKINE; DEXTRAN SULFATE; GAMMA INTERFERON ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 2; PROTEIN; PROTEIN A20; STAT4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANIMAL MODEL; BONE MARROW CELL; CELLULAR IMMUNITY; ENTERITIS; EPITHELIUM CELL; GENE MUTATION; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNITY; IMMUNOREGULATION; INNATE IMMUNITY; INTESTINE FLORA; MICROBIAL ACTIVITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TH1 CELL; TH2 CELL;

ANIMALS; BACTERIA; DISEASE MODELS, ANIMAL; HUMANS; IMMUNITY, MUCOSAL; IMMUNITY, NATURAL; INFLAMMATORY BOWEL DISEASES; MICE;

EID: 23344449020     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0105-2896.2005.00291.x     Document Type: Review

References (147)

1. Macpherson AJ, Uhr T. Induction of protective IgA by intestinal dendritic cells carrying commensal bacteria. Science 2004;303:1662-1665.
2. Konrad A, Cong Y, Duck W, Elson CO. The dominant immune response to intestinal bacterial antigens is ignorance, rather than tolerance. Gastroenterology 2003;124:A60.
3. Takeda K, et al. Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999;10:39-49.
4. Weite T, et al. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc Natl Acad Sci USA 2003;100:1879-1884.
5. Heyninck K, Beyaert R. A20 inhibits NF-kappaB activation by dual ubiquitin-editing functions. Trends Biochem Sci 2005;30:1-4.
6. Lee EG, et al. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000;289:2350-2354.
7. Boone DL, et al. The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol 2004;5:1052-1060.
8. Hoentjen F, Sartor RB, Ozaki M, Jobin C. STAT3 regulates NF-κB recruitment to the IL-12p40 promoter in dendritic cells. Blood 2005;105:689-696.
9. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ. Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002;169:2253-2263.
10. Wahl SM, Hunt DA, Bansal G, McCartney-Francis N, Ellingsworth L, Allen JB. Bacterial cell wall-induced immunosuppression. Role of transforming growth factor beta. J Exp Med 1988;168:1403-1417.
11. Chen W, Frank ME, Jin W, Wahl SM. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001;14:715-725.
12. McCartney-Francis N, Jin W, Wahl SM. Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol 2004;172:3814-3821.
13. Smythies LE, et al. Human intestinal macrophages display profound inflammatory anergy despite avid phagocytic and bacteriocidal activity. J Clin Invest 2005;115:66-75.
14. Schmitz ML, Baeuerle PA. The p65 subunit is responsible for the strong transcription activating potential of NF-kappa B. EMBO J 1991;10:3805-3817.
15. + T lymphocytes. Science 1992;256:1452-1456.
16. Kastenbauer S, Ziegler-Heitbrock HW. NF-kappaB1 (p50) is upregulated in lipopolysaccharide tolerance and can block tumor necrosis factor gene expression. Infect Immun 1999;67:1553-1559.
17. Tomczak MF, et al. NF-kappa B is required within the innate immune system to inhibit microflora-induced colitis and expression of IL-12 p40. J Immunol 2003;171:1484-1492.
18. Girardin SE, et al. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J Biol Chem 2003;278:8869.
19. Hugot JP, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001;411:599-603.
20. Ogura Y, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001;411:603-606.
21. Cuthbert AP, et al. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 2002;122:867-874.
22. Abreu MT, et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002;123:679-688.
23. Ogura Y, et al. Expression of NOD2 in Paneth cells: a possible link to Crohn's ileitis. Gut 2003;52:1591-1597.
24. Lala S, et al. Crohn's disease and the NOD2 gene: a role for Paneth cells. Gastroenterology 2003;125:47-57.
25. Wehkamp J, et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004;53:1658-1664.
26. Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur J Gastroenterol Hepatol 2003;15:627-634.
27. Pauleau AL, Murray PJ. Role of nod2 in the response of macrophages to toll-like receptor agonists. Mol Cell Biol 2003;23:7531-7539.
28. Kobayashi KS, et al. Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract. Science 2005;307:731-734.
29. Maeda S, et al. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing. Science 2005;307:734-738.
30. Watanabe T, Kitani A, Murray PJ, Strober W. NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 2004;5:800-808.
31. McCracken VJ, Lorenz RG. The gastrointestinal ecosystem: a precarious alliance among epithelium, immunity and microbiota. Cell Microbiol 2001;3:1-11.
32. Abreu MT, Fukata M, Arditi M. TLR signaling in the gut in health and disease. J Immunol 2005;174:4453-4460.
33. McCracken VJ, Gaskins HR. Probiotics and the immune system. In: Tannock GW, ed. Probiotics A Critical Review. Norfolk, UK: Horizon Scientific Press, 1999:85.
34. Shirazi T, Longman RJ, Corfield AP, Probert CS. Mucins and inflammatory bowel disease. Postgrad Med J 2000;76:473-478.
35. Juliano RL, Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 1976;455:152-162.
36. Hunter J, Jepson MA, Tsuruo T, Simmons NL, Hirst BH. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J Biol Chem 1993;268:14991-14997.
37. Litman T, Druley TE, Stein WD, Bates SE. From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 2001;58:931-959.
38. Banerjee SK, Jagannath C, Hunter RL, Dasgupta A. Bioavailability of tobramycin after oral delivery in FVB mice using CRL-1605 copolymer, an inhibitor of P-glycoprotein. Life Sci 2000;67:2011-2016.
39. Walle UK, Walle T. Transport of the cooked-food mutagen 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine (PhIP) across the human intestinal Caco-2 cell monolayer: role of efflux pumps. Carcinogenesis 1999;20:2153-2157.
40. Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut 2003;52:759-766.
41. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 1987;84:7735-7738.
42. Stephens RH, Tanianis-Hughes J, Higgs NB, Humphrey M, Warhurst G. Region-dependent modulation of intestinal permeability by drug efflux transporters: in vitro studies in mdr1a(-/-) mouse intestine. J Pharmacol Exp Ther 2002;303:1095-1101.
43. Yacyshyn B, Maksymowych W, Bowen-Yacyshyn MB. Differences in P-glycoprotein-170 expression and activity between Crohn's disease and ulcerative colitis. Hum Immunol 1999;60:677-687.
44. Schwab M, et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003;124:26-33.
45. Hoffmeyer S, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-3478.
46. Panwala CM, Jones JC, Viney JL. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998;161:5733-5744.
47. Maggio-Price L, et al. Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice. Am J Pathol 2002;160:739-751.
48. Banner KH, Cattaneo C, Le Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br J Pharmacol 2004;143:590-598.
49. Lodes MJ, et al. Bacterial flagellin is a dominant antigen in Crohn disease. J Clin Invest 2004;113:1296-1306.
50. Klimecki WT, Futscher BW, Grogan TM, Dalton WS. P-glycoprotein expression and function in circulating blood cells from normal volunteers. Blood 1994;83:2451-2458.
51. Resta-Lenert S, Smitham J, Barrett KE. Epithelial dysfunction associated with the development of colitis in conventionally housed mdr1a -/- mice. Am J Physiol Gastrointest Liver Physiol 2005. DOI: 10.1152/ajpgi.00395.2004.
52. Rudolph U, et al. Gi2 alpha protein deficiency: a model of inflammatory bowel disease. J Clin Immunol 1995;15 (Suppl):101S-105S.
53. Ohman L, Franzen L, Rudolph U, Harriman GR, Hultgren Hornquist E. Immune activation in the intestinal mucosa before the onset of colitis in Galphai2-deficient mice. Scand J Immunol 2000;52:80-90.
54. Velazquez P, Wei B, Braun J. Surveillance B lymphocytes and mucosal immunoregulation. Springer Semin Immunopathol 2005;26:453-462.
55. Neurath M, Fuss I, Strober W. TNBS-colitis. Int Rev Immunol 2000;19:51-62.
56. Boirivant M, Fuss IJ, Chu A, Strober W. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998;188:1929-1939.
57. Sartor RB, Cromartie WJ, Powell DW, Schwab JH. Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments. Gastroenterology 1985;89:587-595.
58. Itoh H, Beck PL, Inoue N, Xavier R, Podolsky DK. A paradoxical reduction in susceptibility to colonic injury upon targeted transgenic ablation of goblet cells. J Clin Invest 1999;104:1539-1547.
59. Yamada T, Deitch E, Specian RD, Perry MA, Sartor RB, Grisham MB. Mechanisms of acute and chronic intestinal inflammation induced by indomethacin. Inflammation 1993;17:641-646.
60. Edalat M, Mannervik B, Axelsson LG. Selective expression of detoxifying glutathione transferases in mouse colon: effect of experimental colitis and the presence of bacteria. Histochem Cell Biol 2004;122:151-159.
61. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990;98:694-702.
62. Kitajima S, Takuma S, Morimoto M. Tissue distribution of dextran sulfate sodium (DSS) in the acute phase of murine DSS-induced colitis. J Vet Med Sci 1999;61:67-70.
63. Melgar S, Karlsson A, Michaelsson E. Acute colitis induced by dextran sulphate sodium progresses into chronicity in C57BL/6 but not in BALB/c mice - correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol 2005;288:G1328. DOI: 10.1152/ajpgi.00467.2004.
64. Dieleman LA, Ridwan BU, Tennyson GS, Beagley KW, Bucy RP, Elson CO. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 1994;107:1643-1652.
65. Yamada M, Ohkusa T, Okayasu I. Occurrence of dysplasia and adenocarcinoma after experimental chronic ulcerative colitis in hamsters induced by dextran sulphate sodium. Gut 1992;33:1521-1527.
66. Rath HC, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001;69:2277-2285.
67. Rachmilewitz D, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004;126:520-528.
68. Verdu EF, et al. Oral administration of antigens from intestinal flora anaerobic bacteria reduces the severity of experimental acute colitis in BALB/c mice. Clin Exp Immunol 2000;120:46-50.
69. Setoyama H, Imaoka A, Ishikawa H, Umesaki Y. Prevention of gut inflammation by Bifidobacterium in dextran sulfate-treated gnotobiotic mice associated with Bacteroides strains isolated from ulcerative colitis patients. Microbes Infect 2003;5:115-127.
70. Mahler M, et al. Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 1998;274:G544-G551.
71. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-241.
72. Araki A, et al. MyD88-deficient mice develop severe intestinal inflammation in dextran sodium sulfate colitis. J Gastroenterol 2005;40:16-23.
73. Bylund-Fellenius AC, Landstrom E, Axelsson LG, Midtvedt T. Experimental colitis induced by dextran sulfate in normal and germfree mice. Microbiol Ecol Health Dis 1994;7:207-217.
74. Kitajima S, Morimoto M, Sagara E, Shimizu C, Ikeda Y. Dextran sodium sulfate-induced colitis in germ-free IQI/Jic mice. Exp Anim 2001:50:387-395.
75. Saparov A, Elson CO, Devore-Carter D, Bucy RP, Weaver CT. Single-cell analyses of CD4+ T cells from alpha beta T cell receptor-transgenic mice: a distinct mucosal cytokine phenotype in the absence of transgene-specific antigen. Eur J Immunol 1997;27:1774-1781.
76. Bucy RP, et al. Heterogeneity of single cell cytokine gene expression in clonal T cell populations. J Exp Med 1994;180:1251-1262.
77. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999;10:387-398.
78. Kontoyiannis D, et al. Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease. J Exp Med 2002;196:1563-1574.
79. Wirtz S, et al. Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF-plus IFN-gamma-producing CD4(+) T cells that respond to bacterial antigens. J Immunol 1999;162:1884-1888.
80. Clegg CH, et al. Thymus dysfunction and chronic inflammatory disease in gp39 transgenic mice. Int Immunol 1997;9:1111-1122.
81. Iqbal N, Oliver JR, Wagner FH, Lazenby AS, Elson CO, Weaver CT. T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis. J Exp Med 2002;195:71-84.
82. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-638.
83. Chen Y, Inobe J, Kuchroo VK, Baron JL, Janeway Jr CA, Weiner HL. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996;93:388-391.
84. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389:737-742.
85. Cong Y, Weaver CT, Lazenby A, Elson CO. Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora. J Immunol 2002;169:6112-6119.
86. + CD25 bright T cells in human intestinal lamina propria as regulatory cells. J Immunol 2004;173:3119-3130.
87. Papiernik M, de Moraes ML, Pontoux C, Vasseur F, Penit C. Regulatory CD4 T cells: expression of IL-2R alpha chain, resistance to clonal deletion and IL-2 dependency. Int Immunol 1998;10:371-378.
88. + regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18-32.
89. + suppressor T cells. Immunol Rev 2001;182:58-67.
90. Takahashi T, Sakaguchi S. The role of regulatory T cells in controlling immunologic self-tolerance. Int Rev Cytol 2003;22S:1-32.
91. + regulatory T cells. Int Immunol 2004;16:1189-1201.
92. Setoguchi R, Hori S, Takahashi T, Sakaguchi S. Homeostatic maintenance of natural FoxpS (+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J Exp Med 2005;201:723-735.
93. Kundig TM, Schorle H, Bachmann MF, Hengartner H, Zinkernagel RM, Horak I. Immune responses in interleukin-2-deficient mice. Science 1993;262:1059-1061.
94. Ma A, Datta M, Margosian E, Chen J, Horak I. T cells, but not B cells, are required for bowel inflammation in interleukin 2-deficient mice. J Exp Med 1995;182:1567-1592.
95. Kramer S, Schimpl A, Hunig T. Immunopathology of interleukin (IL) 2-deficient mice: thymus dependence and suppression by thymus-dependent cells with an intact IL-2 gene. J Exp Med 1995;182:1769-1776.
96. + T cells. Eur J Immunol 1995;25:3053-3059.
97. + T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol 1995;25:2618-2625.
98. Ehrhardt RO, Ludviksson BR, Gray B, Neurath M, Strober W. Induction and prevention of colonic inflammation in IL-2-deficient mice. J Immunol 1997;158:566-573.
99. Contractor NV, et al. Lymphoid hyperplasia, autoimmunity, and compromised intestinal intraepithelial lymphocyte development in colitis-free gnotobiotic IL-2-deficient mice. J Immunol 1998;160:385-394.
100. Poussier P, Ning T, Chen J, Banerjee D, Julius M. Intestinal inflammation observed in IL-2R/IL-2 mutant mice is associated with impaired intestinal T lymphopoiesis. Gastroenterology 2000;118:880-891.
101. Sellon RK, et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun 1998;66:5224-5231.
102. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10- deficient mice develop chronic enterocolitis. Cell 1993;75:263-274.
103. + TH1-like responses. J Clin Invest 1996;98:1010-1020.
104. Rennick DM, Fort MM, Davidson NJ. Studies with IL-10-/- mice: an overview. J Leukoc Biol 1997;61:389-396.
105. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol 1998;161:3143-3149.
106. Ruiz PA, Shkoda A, Kim SC, Sartor RB, Haller D. IL-10 gene-deficient mice lack TGF-beta/Smad signaling and fail to inhibit proinflammatory gene expression in intestinal epithelial cells after the colonization with colitogenic Enterococcus faecalis. J Immunol 2005;174:2990-2999.
107. + T cells from scid mice with inflammatory bowel disease. Eur J Immunol 2001;31:23-31.
108. + T cells. Immunity 1994;1:553-562.
109. + T cells. Am J Pathol 1996;148:1503-1515.
110. Mackay F, et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998;115:1464-1475.
111. +, CD45RBhigh T cells to SCID recipients. J Immunol 1997;158:3464-3473.
112. Matsuda JL, et al. Systemic activation and antigen-driven oligoclonal expansion of T cells in a mouse model of colitis. J Immunol 2000;164:2797-2806.
113. + T cells. J Exp Med 1993;178:237-245.
114. + T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice. Int Immunol 1993;5:1461-1471.
115. + T cells. J Exp Med 1996;183:2669-2674.
116. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 1999;190:995-1004.
117. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med 2000;192:295-302.
118. Annacker O, Burlen-Defranoux O, Pimenta-Araujo R, Cumano A, Bandeira A. Regulatory CD4 T cells control the size of the peripheral activated/memory CD4 T cell compartment. J Immunol 2000;164:3573-3580.
119. Kulkarni AB, et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol 1995;146:264-275.
120. Diebold RJ, et al. Early-onset multifocal inflammation in the transforming growth factor beta 1-null mouse is lymphocyte mediated. Proc Natl Acad Sci USA 1995;92:12215-12219.
121. Boivin GP, Ormsby I, Jones-Carson J, O'Toole BA, Doetschman T. Germ-free and barrier-raised TGF beta 1-deficient mice have similar inflammatory lesions. Transgenic Res 1997;6:197-202.
122. Letterio JJ, et al. Autoimmunity associated with TGF-beta1-deficiency in mice is dependent on MHC class II antigen expression. J Clin Invest 1996;98:2109-2119.
123. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000;12:171-181.
124. Ashcroft GS, et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1999;1:260-266.
125. Neurath MF, Fuss I, Kelsall BL, Presky DH, Waegell W, Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996;183:2605-2616.
126. Ludviksson BR, Ehrhardt RO, Strober W. TGF-beta production regulates the development of the 2,4,6-trinitrophenol-conjugated keyhole limpet hemocyanin-induced colonic inflammation in IL-2-deficient mice. J Immunol 1997;159:3622-3628.
127. Mizoguchi A, Mizoguchi E, Chiba C, Bhan AK. Role of appendix in the development of inflammatory bowel disease in TCR-alpha mutant mice. J Exp Med 1996;184:707-715.
128. + T cells in a transfer model of colitis. J Immunol 1998;161:3256-3261.
129. Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol Rev 1999;169:195-207.
130. Dianda L, Hanby AM, Wright NA, Sebesteny A, Hayday AC, Owen MJ. T cell receptor-alpha beta-deficient mice fail to develop colitis in the absence of a microbial environment. Am J Pathol 1997;150:91-97.
131. Mizoguchi A, Mizoguchi E, Smith RN, Preffer FI, Bhan AK. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997;186:1749-1756.
132. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation. Immunity 2002;16:219-230.
133. Matsumoto S, et al. Inflammatory bowel disease-like enteritis and caecitis in a senescence accelerated mouse P1/Yit strain. Gut 1998;43:71-78.
134. Kosiewicz MM, et al. Th1-type responses mediate spontaneous ileitis in a novel murine model of Crohn's disease. J Clin Invest 2001;107:695-702.
135. Bamias G, et al. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 2005;128:654-666.
136. Olson TS, et al. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J Clin Invest 2004;114:389-398.
137. Burns RC, Rivera-Nieves J, Moskaluk CA, Matsumoto S, Cominelli F, Ley K. Antibody blockade of ICAM-1 and VCAM-1 ameliorates inflammation in the SAMP-1/ Yit adoptive transfer model of Crohn's disease in mice. Gastroenterology 2001;121:1428-1436.
138. + monocytic cell recruitment in intestinal mucosa and ameliorates ileitis in SAMP1/Yit mice. J Leukoc Biol 2005;77:287-295.
139. + T cell recruitment to chronically inflamed small intestine. J Immunol 2005;174:2343-2352.
140. Vidrich A, et al. Altered epithelial cell lineage allocation and global expansion of the crypt epithelial stem cell population are associated with ileitis in SAMP1/YitFc mice. Am J Pathol 2005;166:1055-1067.
141. Tanaka M, et al. Spatial distribution and histogenesis of colorectal Paneth cell metaplasia in idiopathic inflammatory bowel disease. J Gastroenterol Hepatol 2001;16:1353-1359.
142. Grimm MC, Pavli P. NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link? Gut 2004;53:1558-1560.
143. Sundberg JP, Elson CO, Bedigian H, Birkenmeier EH. Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice. Gastroenterology 1994;107:1726-1735.
144. + T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. J Exp Med 1998;187:855-864.
145. + T cell response to bacterial antigens. Gastroenterology 2004;126:A45.
146. Brandwein SL, et al. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J Immunol 1997;159:44-52.
147. Willerford DM, Chen J, Ferry JA, Davidson L, Ma A, Alt FW. Interleukin-2 receptor alpha chain regulates the size and content of the peripheral lymphoid compartment. Immunity 1995;3:521-530.